Evolving Therapeutics for Resectable Esophageal Adenocarcinoma

Area of Science:

• Gastroenterology
• Oncology
• Surgical Oncology

Background:

• Surgical resection is the primary curative treatment for localized esophageal adenocarcinoma.
• Resection alone is inadequate for locally advanced disease due to high recurrence rates.
• Current multimodal strategies have improved survival but a significant unmet need persists.

Purpose of the Study:

• To review evidence-based and emerging perioperative strategies for esophageal adenocarcinoma.
• To explore risk-adapted approaches for individualizing perioperative therapy.
• To address resistance to cytotoxic therapies in locally advanced esophageal adenocarcinoma.

Main Methods:

• Review of current literature on perioperative treatments for esophageal adenocarcinoma.
• Analysis of survival data for various treatment modalities.
• Discussion of novel therapeutic strategies and risk stratification.

Main Results:

• Perioperative chemotherapy, chemoradiotherapy, and immune checkpoint blockade improve survival.
• Approximately 50% of patients with locally advanced disease still experience recurrence.
• Resistance to cytotoxic therapy necessitates the development of novel treatment approaches.

Conclusions:

• Multimodal perioperative therapy is crucial for locally advanced esophageal adenocarcinoma.
• Further research is needed to overcome treatment resistance.
• Individualized, risk-adapted perioperative strategies hold promise for improving patient outcomes.